AUTHORS
Evelyn Hastings Orlando, MD, Yuxuan Chen, PhD2, Geoffrey K Dube, MD3, Heather Morris, MD4, Selim Arcasoy, MD, MPH5, Farhana Latif, MD6, Ersilia M DeFilippis, MD7, Mercedes Martinez, MD8, Gene Y Im, MD9, Meaghan M Phipps, MD10, Russell Rosenblatt, MD, MS11, David T Majure, MD, MPH12, Darshana M Dadhania, MD, MS13, Zahraa Khan, MB, BS14, Marcus R Pereira, MD, MPH15, Manuela Orjuela, MD16, Amy Chadburn, M.D.17, Giorgio Inghirami, MD18, Jia Ruan, MD, PhD19, Gaston Jean-Louis, MD20, Andrew Lipsky, MD21, Seda S. Tolu, MD22, Ran Reshef, MD, MSc23, Barbara Pro, MD24, Hua-Jay Jeffery Cherng, MD25, Jennifer Effie Amengual, MD26
AFFILIATIONS
2 Columbia University Irving Medical Center, NEW YORK, United States
3 Columbia University Irving Medical Center, NEW YORK, United States
4 Columbia University Irving Medical Center, NEW YORK, United States
5 Columbia University Irving Medical Center, NEW YORK, United States
6 Columbia University Irving Medical Center, NEW YORK, United States
7 Columbia University Irving Medical Center, NEW YORK, United States
8 Columbia University Irving Medical Center, NEW YORK, United States
9 Columbia University Irving Medical Center, NEW YORK, United States
10 Columbia University Irving Medical Center, NEW YORK, United States
11 Weill Cornell Medicine, NEW YORK, United States
12 Weill Cornell Medicine, NEW YORK, United States
13 Weill Cornell Medicine, NEW YORK, United States
14 Weill Cornell Medicine, NEW YORK, United States
15 Columbia University Irving Medical Center, NEW YORK, United States
16 Columbia University Irving Medical Center, NEW YORK, United States
17 Weill Cornell Medicine, NEW YORK, United States
18 Weill Cornell Medicine, NEW YORK, United States
19 Weill Cornell Medicine, NEW YORK, United States
20 Columbia University Irving Medical Center, NEW YORK, United States
21 Columbia University Irving Medical Center, NEW YORK, United States
22 Columbia University Irving Medical Center, NEW YORK, United States
23 Columbia University Irving Medical Center, NEW YORK, United States
24 Columbia University Irving Medical Center, NEW YORK, United States
25 Columbia University Irving Medical Center, NEW YORK, United States
26 Columbia University Irving Medical Center, NEW YORK, United States
ABSTRACT
Background and Significance:
Posttransplant lymphoproliferative disorder (PTLD) is a major contributor to morbidity and mortality after solid organ transplantation (SOT). PTLD occurs in up to 20% of SOT recipients and is associated with an overall survival rate of 59% at 2 years in high-risk patients. Epstein-Barr virus (EBV) infection is associated with over 60% of cases of PTLD. EBV reactivation occurs in up to 45% of SOT recipients. Antiviral therapies are not effective for clearance of EBV DNAemia. Standard practice for treatment of EBV DNAemia in SOT recipients is to reduce immunosuppression (IS). However, reduction of IS is not always effective in clearing EBV or preventing PTLD and is associated with a significant risk of graft rejection. Additional strategies are needed to treat EBV DNAemia after SOT to prevent PTLD. Rituximab has been well studied and used successfully for EBV DNAemia in bone marrow transplant recipients. There is a paucity of data for rituximab use after SOT for treatment of EBV DNAemia and prevention of PTLD. We conducted a retrospective study and found that rituximab use in EBV-positive SOT recipients was associated with improved PTLD-free survival [n=1386, HR 0.16, p=0.01] (Orlando et al, Blood Neoplasia 2025). Limitations in this study included heterogeneity in the indication for, timing of, and number of doses of rituximab as well as in the frequency of EBV monitoring. A prospective study is needed to determine whether rituximab should be used to treat EBV DNAemia in SOT recipients with the goal of preventing EBV-associated PTLD.
Study Design and Methods:
NCT07614282 is a prospective pilot/phase II study to evaluate the efficacy of rituximab for clearance of EBV (pilot trial) and for prevention of EBV-associated PTLD (phase II trial) in SOT recipients with EBV reactivation to ≥1000IU/mL (plasma). The pilot trial is a single arm study where SOT recipients with EBV ≥1000IU/mL will receive one dose of rituximab 375mg/m2. Eligible patients include SOT recipients age 18 or older with persistent EBV DNAemia ≥1000IU/mL after reduction of IS regimen, or in whom IS cannot be safely reduced. The primary endpoint of the pilot trial is complete response rate in EBV DNAemia by 6 months. Complete response (CR) is defined as improvement in EBV DNAemia to below the limit of detection. Partial response (PR) is defined as a decrease in viral load of at least 50% from baseline. Secondary endpoints include event-free survival (with events inclusive of development of PTLD, receipt of rituximab for non-protocol indications, second dose of rituximab for rising EBV, or death), grade 3-4 infectious adverse events, all serious adverse events, deaths, and rate of graft rejection. Patients will be followed for one year in the pilot trial. The goal CR rate in the pilot trial is 60%; if this CR rate in EBV DNAemia is achieved in the pilot trial, then the phase II portion of the trial will proceed. The phase II trial is a randomized trial of rituximab in addition to standard of care reduction in IS vs reduction in IS alone for SOT recipients with EBV reactivation to ≥1000IU/mL (plasma). The primary endpoint of the phase II trial is PTLD-free survival. The secondary endpoints of the phase II trial are the same as those listed above for the pilot trial. Patients will be followed for 5 years in the phase II trial. Blood will be collected at baseline and following rituximab administration and banked for future correlative analyses including T cell phenotyping. This is a trial in progress. The pilot trial is expected to accrue 28 patients at one site (Columbia University). The phase II trial is expected to accrue 204 patients at two sites (Columbia University, Weill Cornell).
Funding sources: Research Stabilization Fund from the Department of Medicine at Columbia University Irving Medical Center and support from the Stewart Family Fund
DISCLOSURES
Evelyn Hastings Orlando, MD: No relevant conflicts of interest to declare.